Video

Increased Risk of Tardive Dyskinesia

Author(s):

John J. Miller, MD

How could drugs that block post-synaptic dopamine 2 receptors increase the risk for tardive dyskinesia over time?

John J. Miller, MD, talks about the increased risk of tardive dyskinesia on a synaptic level.

Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!
Related Videos
Psychiatric Times Experts Weight in on FDA Advisory Decision for PTSD
NAIMAH/Adobe Stock
crizzystudio/Adobe Stock
freshidea/Adobe Stock
New Africa /Adobestock
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
Related Content
tardive dyskinesia
June 13th 2025

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

John J. Miller, MD
tardive versus spontaneous dyskinesia
April 17th 2019

Not All That Writhes Is Tardive Dyskinesia

Chris Aiken, MD
tardive dyskinesia
March 20th 2025

New 48-Week Remission Data on Ingrezza for the Treatment of Tardive Dyskinesia

Leah Kuntz
phase 1
March 5th 2025

Phase 1 Study Initiated: NBI-1140675 for Neurological and Neuropsychiatric Conditions

Leah Kuntz
tardive dyskinesia
February 27th 2025

Significant Improvements in Functionality and Quality of Life: New Data on Ingrezza for Tardive Dyskinesia

Leah Kuntz
innovation
December 10th 2024

Psychopharmacology Innovations

John J. Miller, MD
© 2025 MJH Life Sciences

All rights reserved.